Biofrontera Inc.

BFRI | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.16

-$0.16 (-12.12%)

At close: Sep 21, 2026, 4:00 PM ET

$1.20

+$0.04 (+3.45%)

After-hours: Sep 21, 2026, 7:57 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Key Executives

Name	Position
Hermann Luebbert	Chief Executive Officer, President & Chairman
Eugene Frederick Leffler	Chief Financial Officer
Daniel Hakansson	Senior Corporate Counsel
Erica F. Gates	VP of Finance & Principal Accounting Officer
George Jones	Chief Commercial Officer
Jon Lyons	Vice President of Scientific & Medical Affairs
Samantha Widdicombe	Senior Vice President of Sales & Strategic Accounts

Latest SEC Filings

Date	Type	Title
Aug 13, 2026	10-Q	Quarterly Report
Aug 13, 2026	8-K	Current Report
Aug 12, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Jul 29, 2026	4	Filing
Jul 29, 2026	4	Filing
Jul 22, 2026	S-8	Filing
Jul 22, 2026	10-K/A	[Amend] Annual Report
Jun 17, 2026	8-K	Current Report
May 14, 2026	10-Q	Quarterly Report
May 14, 2026	8-K	Current Report

View All SEC Filings ➞

Biofrontera Inc.

Country	United States
IPO Date	Oct 28, 2021
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	89
CEO	Hermann Lübbert

Contact Details

660 Main Street Woburn, Massachusetts 01801 United States

https://www.biofrontera-us.com

781 245 1325

Stock Details

Ticker Symbol	BFRI
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001858685
CUSIP Number	09077D209
ISIN Number	US09077D2099
SIC Code	2834